Drug Profile

MTM H 001

Alternative Names: MTM-H-001

Latest Information Update: 24 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 May 2026 Beijing GoBroad Hospital plans a dose-escalation and expansion basket study of MTM-H-001 for Autoimmune disorders in China in June 2026 (Parentral, injection) (NCT07593911)
24 Mar 2026 Investigation in Haematological malignancies in USA (Parenteral) prior to March 2026 (NCT07476378)
17 Mar 2026 MagicTime Medicine in collaboration with Cancer Institute and Hospital, Chinese Academy of Medical Sciences plans a Archonc-001 trial for Chronic lymphocytic leukemia and Non Hodgkin's lymphoma (Second line therapy or greater) in China (Parenteral, Injection) in March 2026 (NCT07476378)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com